Contributions of fasting and postprandial plasma glucose levels to glycosylated hemoglobin and diabetes mellitus-related complications: Treating hyperglycemia with insulin

Insulin

Volumn 1, Issue 4, 2006, Pages 148-157

  Dailey, George E ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

AIC; fasting plasma glucose; hypoglycemia; rapid acting insulin analogue

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING DRUG; ORAL ANTIDIABETIC AGENT;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; INSULIN HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS SECRETION; POSTPRANDIAL STATE; SYSTEMATIC REVIEW; TREATMENT PLANNING;

EID: 33845884898     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(06)80035-7     Document Type: Article

References (50)

1. Available at:. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Accessed March 15, 2006 (2005), US Dept of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Go. http:///www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf
2. American Diabetes Association. Standards of medical care in diabetes [published correction appears in Diabetes Care. 2005;28:990]. Diabetes Care 28 Suppl 1 (2005) S4-S36
3. American College of Endocrinology. Consensus statement on guidelines for glycemic control. Endocr Pract. 8 Suppl 1 (2002) 511
4. Resnick H.E., Foster G.L., Bardsley J., and Ratner R.E. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002: The National Health and Nutrition Examination Survey. Diabetes Care 29 (2006) 531-537
5. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
6. Rohlfing C.L., Wiedmeyer H.M., Little R.R., et al. Defining the relationship between plasma glucose and HbA(1 c): Analysis of glucose profiles and HbA(1 c) in the Diabetes Control and Complications Trial. Diabetes Care 25 (2002) 275-278
7. Khaw K.T., Wareham N., Bingham S., et al. Association of hemoglobin Al c with cardiovascular disease and mortality in adults: The European Prospective Investigation into Cancer in Norfolk. Ann Intern Med. 141 (2004) 413-420
8. Khaw K.T., Wareham N., Luben R., et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPICNorfolk). BMJ 322 (2001) 15-18
9. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet 352 (1998) 837-853
11. Gerich J.E. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 163 (2003) 1306-1316
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329 (1993) 977-986
13. Nathan D.M., Lachin J., Cleary P., et al., Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 348 (2003) 2294-2303
14. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes 156 four years after a trial of intensive therapy. N Engl J Med. 342 (2000) 381-389
15. Nathan D.M., Cleary P.A., Backlund J.Y., et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 353 (2005) 2643-2653
16. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1 c). Diabetes Care 26 (2003) 881-885
17. Riddle M.C. Evening insulin strategy. Diabetes Care 13 (1990) 676-686
18. Carroll M.F., Izard A., Riboni K., et al. Fasting hyperglycemia predicts the magnitude of postprandial hyperglycemia: Implications for diabetes therapy. Diabetes Care 25 (2002) 1247-1248
19. Tanne D., Koren-Morag N., and Goldbourt U. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: A prospective cohort study. Stroke 35 (2004) 2351-2355
20. Goldberg R.B., Mellies M.J., Sacks F.M., et al., Care Investigators. Cardiovascular events and their reduction with provastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup Analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 98 (1998) 2513-2519
21. Laakso M., and Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rey 5 (1997) 294-315
22. Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes?. Eur J Clin Invest. 30 Suppl 2 (2000) 3-11
23. Bonora E., and Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: The epidemiological evidence. Diabetologia 44 (2001) 2107-2114
24. Coutinho M., Gerstein H.C., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 (1999) 233-240
25. DECODE Study Group and the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 161 (2001) 397-405
26. Tominaga M., Eguchi H., Manaka H., et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 (1999) 920-924
27. Saydah S.H., Loria C.M., Eberhardt M.S., and Brancati F.L. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 24 (2001) 447-453
28. de Vegt F., Dekker J.M., Ruhe H.G., et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: The Hoorn Study. Diabetologia 42 (1999) 926-931
29. Hanefeld M., Koehler C., Schaper F., et al. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 144 (1999) 229-235
30. Barzilay J.I., Spiekerman C.F., Wahl P.W., et al. Cardiovascular disease in older adults with glucose disorders: Comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 354 (1999) 622-625
31. Lebovitz H.E. Effect of the postprandial state on nontraditional risk factors. Am J Cordial. 88 (2001) 20H-25H
32. King G.L., and Wakasaki H. Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. Diabetes Care 22 Suppl 3 (1999) C31-C37
33. Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications 15 (2001) 203-210
34. Riddle M.C., Rosenstock J., Gerich J., and Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
35. DeWitt D.E., and Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 289 (2003) 2254-2264
36. Dailey G.E., Noor M.A., Park J.S., et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial. Am J Med. 116 (2004) 223-229
37. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
38. Riddle M.C. Making the transition from oral to insulin therapy. Am J Med. 118 Suppl 5A (2005) 14S-20S
39. Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus. Clin Ther. 26 (2004) 889-901
40. Hirsch I.B. Insulin analogues. N Engl J Med. 352 (2005) 174-183
41. Paris, France, Abstract 785. Bott S., Tusek C., Jacobsen L.V., et al. Insulin detemir reaches steady-state after the first day of treatment and shows a peakless time-action profile with twice daily-applications. Presented at: 18th Congress of the International Diabetes Federation (August 24-29, 2003)
42. Ratner R.E., Hirsch I.B., Neifing J.L., et al., US Study Group of Insulin Glargine in Type 1 Diabetes. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 23 (2000) 639-643
43. Raskin P., Klaff L., Bergenstal R., et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23 (2000) 1666-1671
44. Rosenstock J., Schwartz S.L., Clark Jr. C.M., et al. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
45. Rosenstock J., Dailey G., Massi-Benedetti M., et al. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28 (2005) 950-955
46. Davies M., Storms F., Shutler S., et al., ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 28 (2005) 1282-1288
47. Abstract 642-P. Yki Jarvinen H., Haring H.-U., Johnson E., et al. The relationship between glycemic control and hypoglycemia using insulin glargine versus NPH insulin: A meta-regression analysis in type 2 diabetes. Diabetes 52 Suppl 1 (2003)
48. Bell D.S. Type 2 diabetes mellitus: What is the optimal treatment regimen?. Am J Med. 116 Suppl 5A (2004) 23S-29S
49. Raskin P., Allen E., Hollander P., et al., INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
50. Bode B.W., Sabbah H.T., Gross T.M., et al. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metob Res Rev. 18 Suppl 1 (2002) S14-S20